AGT and benign prostatic hyperplasia: Some of the cardiovascular medications (antithrombotic agents, calcium channel blockers, angiotensin II antagonists, lipid-modifying agents) and benign prostatic hypertrophy agents were associated with an increased risk of FRIs only in the case-crossover design.